Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
JMP Securities Downgrades Vitae Pharmaceuticals (VTAE) to Market Perform
August 4, 2016 7:21 AM EDTJMP Securities downgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Market Outperform to Market Perform and removed its price target (prior $10.00).
For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.
Shares of Vitae Pharmaceuticals closed at $10.29 yesterday.
... MoreVitae Pharmaceuticals (VTAE) Tops Q2 EPS by 5c
August 3, 2016 5:40 PM EDTVitae Pharmaceuticals (NASDAQ: VTAE) reported Q2 EPS of ($0.36), $0.05 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.3 thousand versus the consensus estimate of $10 thousand.
As of June 30, 2016, Vitae had $77.4 million in cash, cash equivalents and marketable securities, compared with $59.4 million... More
